Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants

• Váldodahkkit: Ye Chan Park (Dahkki), Jae Hoon Kim (Dahkki), Sung Hyun Kim (Dahkki), Ju Hyun Lee (Dahkki), Jang Hee Hong (Dahkki), Jin‐Gyu Jung (Dahkki), Jung Sunwoo (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract CT‐P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation. The subcutaneous (SC) formulation of CT‐P13 overcomes the drawback of prolonged administration associated with the intr...